Medpace Investors Invited to Seek Lead Role in Securities Suit by June 8

Two plaintiff firms are now recruiting shareholders to steer the early-stage case over alleged misstatements.

Overview

Rosen Law Firm and Robbins Geller urged Medpace shareholders to seek appointment as lead plaintiff by June 8, 2026 for trades made from April 22, 2025 through February 9, 2026.
Filed in the Southern District of Ohio, the case is captioned Durbin v. Medpace Holdings Inc., No. 26-cv-00346, and cites alleged violations of the Securities Exchange Act of 1934.
The complaint says Medpace misled investors about rising backlog cancellations and oversold a promised 1.15 book-to-bill ratio for fourth-quarter 2025.
After Medpace reported a 1.04 book-to-bill ratio on February 9, 2026, the stock fell nearly 16% according to the complaint, which frames that drop as investor harm.
No class has been certified, and under the PSLRA the investor with the largest loss typically seeks the lead role and chooses counsel, while others can remain absent class members without taking action.